Prostate cancer is one of the leading
causes of cancer-related
death in men. The identification of new therapeutics to selectively
target prostate cancer cells is therefore vital. Recently, the rotenoids
rotenone (1) and deguelin (2) were reported
to selectively kill prostate cancer cells, and the inhibition of mitochondrial
complex I was established as essential to their mechanism of action.
However, these hydrophobic rotenoids readily cross the blood–brain
barrier and induce symptoms characteristic of Parkinson’s disease
in animals. Since hydroxylated derivatives of 1 and 2 are more hydrophilic and less likely to readily cross the
blood–brain barrier, 29 natural and unnatural hydroxylated
derivatives of 1 and 2 were synthesized
for evaluation. The inhibitory potency (IC50) of each derivative
against complex I was measured, and its hydrophobicity (Slog10P) predicted. Amorphigenin (3), dalpanol (4), dihydroamorphigenin (5), and amorphigenol (6) were selected and evaluated in cell-based assays using
C4-2 and C4-2B prostate cancer cells alongside control PNT2 prostate
cells. These rotenoids inhibit complex I in cells, decrease oxygen
consumption, and selectively inhibit the proliferation of prostate
cancer cells, leaving control cells unaffected. The greatest selectivity
and antiproliferative effects were observed with 3 and 5. The data highlight these molecules as promising therapeutic
candidates for further evaluation in prostate cancer models.